Abcam, ab259168, Human SUCLG2 knockout HEK-293T cell lysate

Size: 1Kit
SUCLG2 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SUCLG2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The SUCLG2 protein also known as succinyl-CoA synthetase GDP-forming beta subunit is an essential component of cellular energy metabolism. It has an approximate molecular mass of 50 kDa. SUCLG2 is primarily expressed in various tissues including liver kidney and heart. It forms part of the succinyl-CoA synthetase enzyme complex which plays a role in the conversion of succinyl-CoA to succinate in the mitochondrial matrix.
Biological function summary
SUCLG2 contributes to the production of GTP through substrate-level phosphorylation an important step in the tricarboxylic acid (TCA) cycle. As part of the succinyl-CoA synthetase complex it aids in the intricate process of energy conversion within mitochondria. The enzymatic activity of SUCLG2 ensures the proper balance of GTP within cells influencing various metabolic processes essential for cellular function and maintenance.
Pathways
SUCLG2 operates within the TCA cycle and is a pivotal link in cellular respiration. In this pathway it ensures the conversion of carbon and energy flow important for energy production. SUCLG2's role here is closely related to the protein SUCLG1 with which it forms the functional succinyl-CoA synthetase complex. Additionally SUCLG2 participates in metabolic pathways related to the biosynthesis of amino acids further extending its influence on cellular metabolism.
SUCLG2 mutations have been implicated in mitochondrial diseases particularly those affecting energy metabolism. For instance patients with such mutations might experience metabolic myopathy syndromes. SUCLG2 also displays connections with SUCLG1 in these disorders given their role in the same enzymatic complex. Recognition of these associations helps in understanding the molecular basis of certain metabolic syndromes and potential avenues for therapeutic intervention.